Calcium Channel Blockers and NSAIDs in Maternal Tocolysis

Preterm birth remains the single largest contributor to perinatal mortality across Australia, with roughly 8% of babies born before 37 weeks each year according to national perinatal datasets. When a woman presents with threatened preterm labour before 34 weeks, clinicians often reach for agents that can quiet the myometrium long enough to administer antenatal corticosteroids, transfer the mother to a tertiary centre, or complete magnesium sulphate neuroprotection. Choosing between calcium channel blockers and non-steroidal anti-inflammatory drugs shapes both the maternal experience and the neonatal course in ways that deserve a careful side-by-side review.

The pharmacological aim of tocolysis is uterine relaxation rather than cure, and the two most widely used non-steroidal options act through entirely different pathways. Understanding those pathways is the first step in matching the right drug to the right patient, particularly in Australian maternity units where rural transfers and shared-care arrangements add practical complexity to every decision.

How the Two Drug Classes Quiet the Myometrium

Nifedipine, the calcium channel blocker most commonly used for tocolysis, blocks voltage-gated L-type calcium channels in myometrial smooth muscle. Calcium entry drives actin-myosin cross-bridging, so limiting that influx reduces the frequency and amplitude of contractions. The drug is given orally, reaches peak plasma levels within 30 to 60 minutes, and has a half-life long enough to allow twice or three times daily dosing during acute therapy.

Non-steroidal anti-inflammatory tocolytics, principally indomethacin and sometimes ibuprofen, work upstream of the contractile machinery. By inhibiting cyclo-oxygenase, they suppress prostaglandin synthesis, and prostaglandins are among the most potent stimulants of uterine activity. Indomethacin can be given orally or rectally, achieves rapid absorption, and crosses the placenta readily, which is precisely why its fetal effects demand attention.

The clinical consequence of these mechanistic differences is that the two classes do not compete on the same axis. CCBs reduce excitability of an already active uterus, while NSAIDs remove one of the chemical signals that drives that activity in the first place. Choosing between them therefore becomes a question of maternal comorbidities, gestational age, and how quickly an effect is needed.

Efficacy in Randomised Trials and Meta-Analyses

Head-to-head randomised trials and Cochrane reviews have repeatedly shown that nifedipine and indomethacin achieve broadly similar outcomes in delaying delivery by 48 hours, the benchmark interval that allows a full corticosteroid course. Network meta-analyses place nifedipine among the most effective tocolytics for this endpoint, with indomethacin performing comparably when used before 32 weeks.

Beyond 48 hours, the picture is murkier. Most trials are not powered to detect differences in latency beyond seven days, in birthweight, or in composite neonatal morbidity. Some subgroup analyses have suggested that nifedipine may produce slightly longer latency in nulliparous women, while indomethacin may perform better when there is evidence of prostaglandin-driven labour such as a short cervix with funneling on transvaginal ultrasound.

A practical point that often gets lost in efficacy debates is that any tocolytic is only as useful as the system around it. In a busy birth suite at the Women's at Sandringham or a tertiary unit such as King Edward Memorial in Perth, the drug that fits existing observation protocols and is already familiar to midwifery staff will often produce better real-world outcomes than a theoretically superior agent prescribed by a consultant who is not on the floor.

Maternal Safety and Tolerability

The side effect profiles diverge more sharply than the efficacy data. Nifedipine can cause peripheral vasodilation, leading to flushing, headache, palpitations, and a measurable drop in blood pressure that is occasionally symptomatic enough to warrant fluid loading or switching agents. These effects are usually self-limiting and rarely serious in volume-replete women, but they can mimic the symptoms of pulmonary embolism or placental abruption, which is why clear documentation matters when a mother complains of sudden chest tightness after her first dose.

NSAIDs used as tocolytics carry their own maternal baggage. Indomethacin and ibuprofen can irritate the gastric mucosa, impair platelet aggregation, and in rare cases precipitate maternal renal impairment, particularly in the setting of pre-eclampsia where renal perfusion is already compromised. The bleeding risk is small at tocolytic doses but not zero, and the gastritis risk is real enough that many Australian pharmacists counsel women to take the drug with food.

Both classes are contraindicated in specific maternal circumstances. Nifedipine should be avoided in women with severe aortic stenosis or fixed cardiac output states, while indomethacin is generally withheld where there is maternal coagulopathy, significant peptic ulcer disease, or renal insufficiency. RANZCOG statements consistently emphasise that tocolysis is a tool rather than a treatment, and that the underlying indication for preterm labour must always be reviewed in parallel.

Fetal and Neonatal Considerations

The neonatal story is where the two agents diverge most clearly. Indomethacin crosses the placenta and inhibits prostaglandin-mediated patency of the ductus arteriosus. Used after about 32 weeks, or for more than 48 hours at any gestational age, it has been associated with premature ductal closure and with oligohydramnios secondary to reduced fetal urine output. Both effects usually reverse after the drug is stopped, but they are not trivial, and they are the main reason indomethacin tends to be reserved for gestations below 32 weeks in Australian practice.

Nifedipine has a more reassuring fetal profile in most observational data. There is no convincing signal of ductal constriction, and the drug does not appear to reduce amniotic fluid volume in the same way. The neonatal concerns are indirect: maternal hypotension can occasionally compromise uteroplacental perfusion, and babies born to mothers on multiple antihypertensives may need closer monitoring in the first 24 hours.

After birth, both classes of mother can present infants whose glucose regulation needs particular attention, especially if antenatal betamethasone has been administered alongside tocolysis. Australian midwives routinely screen babies according to local protocols, and contemporary guidance on thresholds and treatment pathways is summarised in resources such as the neonatal hypoglycemia thresholds discussion from the FAOPS 2020 meeting materials.

Australian Practice, Guidelines, and Access

RANZCOG's statements on the management of preterm labour consistently recommend nifedipine as a first-line tocolytic, with indomethacin listed as an alternative when nifedipine is contraindicated or not tolerated, and with a clear gestational ceiling for NSAID use. The Pharmaceutical Benefits Scheme subsidises nifedipine for this indication, and indomethacin suppositories are widely available through hospital pharmacies, which means cost is rarely a barrier in public care.

Geography shapes Australian tocolysis in ways that textbooks from London or Boston rarely capture. A woman presenting at 30 weeks in Broome, Alice Springs, or Mount Isa may need to be transferred hundreds of kilometres by the Royal Flying Doctor Service before she reaches a neonatal intensive care unit. In that context, a tocolytic that delays delivery reliably for even 24 hours can change the outcome, and the familiarity of the drug for the retrieval team matters as much as its theoretical efficacy.

Australian clinicians have also had to absorb the consequences of the COVID-19 pandemic, which disrupted perinatal services globally and shifted the epidemiology of preterm birth in several regions. The pandemic-era experience is examined in detail in the COVID-19 perinatal mortality analysis from the same FAOPS 2020 collection, and it remains a useful reminder that tocolysis sits inside a much larger system of maternity and neonatal care.

Practical Recommendations for Australian Maternity Units

• Use nifedipine as the first-line oral tocolytic for gestations between 24 and 34 weeks when there are no maternal contraindications.
• Reserve indomethacin for gestations under 32 weeks when nifedipine is not tolerated or is contraindicated, and limit continuous use to 48 hours where possible.
• Document maternal blood pressure, heart rate, and symptoms within 30 minutes of each nifedipine dose, and have a clear escalation pathway for symptomatic hypotension.
• Check renal function, platelet count, and a coagulation baseline before starting indomethacin in any woman with suspected pre-eclampsia or abruption.
• Arrange fetal echocardiography or ductal assessment if indomethacin has been used beyond 48 hours or after 32 weeks.
• Coordinate with retrieval services early when transfer is anticipated, and choose the tocolytic the receiving unit is most familiar with whenever clinical equipoise exists.
• Audit tocolysis outcomes annually at the unit level, including latency, gestational age at delivery, and major neonatal morbidity, and feed the data back to multidisciplinary meetings.

For clinicians who want to revisit the broader scientific programme that informed many of these discussions, the abstracts and speaker materials from the cancelled FAOPS 2020 congress remain available online and continue to support teaching and protocol review across the region.